Affiliation:
1. Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Dr. Aboujaoude, 401 Quarry Road, Room 2301, Stanford, CA 94305, United States
Abstract
Many patients with OCD respond partially or not at all to standard medications and
cognitive behavioral therapy approaches, making alternate treatments necessary. We review
the preliminary evidence that exists in support of the use of stimulants, high-dose caffeine,
opiates, memantine, ondansetron, ketamine, and transcranial magnetic stimulation in some
patients with OCD. Although limited by small or modest sample sizes, open-label study designs,
and brief follow-up periods, studies suggest that each of these strategies can help some
patients who have inadequately responded to first-line treatments. The existing data and the
unmet needs of OCD patients justify research attention to further test these treatments’ safety
and efficacy. Previously untested drugs also deserve attention, especially as recent research
has suggested new possible contributors to OCD pathophysiology. Similarly, psychotherapeutic
interventions beyond CBT should be investigated, and treatments with preliminary evidence
in OCD, including Acceptance Commitment Therapy, Danger Ideation Reduction
Therapy, and technology-enabled interventions like computerized CBT and Virtual Reality
Exposure Therapy, should be carefully tested.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Reference41 articles.
1. Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder.
2. Price L, Rasmussen S, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. II. Validity.
3. Deacon BJ. Psychometric properties and construct validity of the Obsessive-Compulsive Inventory - Revised: Replication and extension with a clinical sample.
4. Lewander T, Malm U, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat).
5. Hamilton JA, Guttmacher LB, Murphy DL. D-amphetamine in obsessive-compulsive disorder.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献